Grape King Bio Ltd produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy foods in Taiwan, China, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$162.50|
|52 Week High||NT$160.50|
|52 Week Low||NT$190.50|
|1 Month Change||-1.22%|
|3 Month Change||-3.56%|
|1 Year Change||-9.72%|
|3 Year Change||-22.25%|
|5 Year Change||-37.98%|
|Change since IPO||156.92%|
Recent News & Updates
Grape King Bio (TPE:1707) Knows How To Allocate Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Here's Why Grape King Bio (TPE:1707) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|1707||TW Personal Products||TW Market|
Return vs Industry: 1707 exceeded the TW Personal Products industry which returned -14% over the past year.
Return vs Market: 1707 underperformed the TW Market which returned 33.6% over the past year.
Stable Share Price: 1707 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: 1707's weekly volatility (2%) has been stable over the past year.
About the Company
Grape King Bio Ltd produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy foods in Taiwan, China, and internationally. It operates through Multi-Level Marketing, Distributors, and Original Design Manufacturer/Original Equipment Manufacturer (ODM/OEM) segments. The company offers mushroom mycelium products, such as ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor; probiotics, including enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium; and enzymes.
Grape King Bio Fundamentals Summary
|1707 fundamental statistics|
Is 1707 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1707 income statement (TTM)|
|Cost of Revenue||NT$1.80b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||9.06|
|Net Profit Margin||13.67%|
How did 1707 perform over the long term?See historical performance and comparison
3.9%Current Dividend Yield
Is Grape King Bio undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1707 (NT$162.5) is trading below our estimate of fair value (NT$203.26)
Significantly Below Fair Value: 1707 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1707 is poor value based on its PE Ratio (18.8x) compared to the TW Personal Products industry average (15x).
PE vs Market: 1707 is poor value based on its PE Ratio (18.8x) compared to the TW market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: 1707 is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: 1707 is overvalued based on its PB Ratio (2.6x) compared to the TW Personal Products industry average (2x).
How is Grape King Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1707's forecast earnings growth (9.6% per year) is above the savings rate (0.8%).
Earnings vs Market: 1707's earnings (9.6% per year) are forecast to grow faster than the TW market (8.6% per year).
High Growth Earnings: 1707's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1707's revenue (6.5% per year) is forecast to grow slower than the TW market (9.5% per year).
High Growth Revenue: 1707's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1707's Return on Equity is forecast to be low in 3 years time (16.3%).
How has Grape King Bio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1707 has high quality earnings.
Growing Profit Margin: 1707's current net profit margins (13.7%) are lower than last year (14.1%).
Past Earnings Growth Analysis
Earnings Trend: 1707's earnings have grown by 0.4% per year over the past 5 years.
Accelerating Growth: 1707's earnings growth over the past year (0.3%) is below its 5-year average (0.4% per year).
Earnings vs Industry: 1707 earnings growth over the past year (0.3%) underperformed the Personal Products industry 17.9%.
Return on Equity
High ROE: 1707's Return on Equity (18.6%) is considered low.
How is Grape King Bio's financial position?
Financial Position Analysis
Short Term Liabilities: 1707's short term assets (NT$4.5B) exceed its short term liabilities (NT$2.9B).
Long Term Liabilities: 1707's short term assets (NT$4.5B) exceed its long term liabilities (NT$433.2M).
Debt to Equity History and Analysis
Debt Level: 1707's debt to equity ratio (2.1%) is considered satisfactory.
Reducing Debt: 1707's debt to equity ratio has reduced from 53% to 2.1% over the past 5 years.
Debt Coverage: 1707's debt is well covered by operating cash flow (1200.7%).
Interest Coverage: 1707's interest payments on its debt are well covered by EBIT (609.6x coverage).
What is Grape King Bio current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1707's dividend (3.94%) is higher than the bottom 25% of dividend payers in the TW market (1.94%).
High Dividend: 1707's dividend (3.94%) is low compared to the top 25% of dividend payers in the TW market (5.25%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 1707 has been paying a dividend for less than 10 years.
Growing Dividend: 1707's dividend payments have increased, but the company has only paid a dividend for 7 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (70.6%), 1707's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 1707's dividends in 3 years are forecast to be covered by earnings (68.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Grape King Bio has no CEO, or we have no data on them.
Experienced Management: 1707's management team is seasoned and experienced (6.8 years average tenure).
Experienced Board: 1707's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.9%.
Grape King Bio Ltd's employee growth, exchange listings and data sources
- Name: Grape King Bio Ltd
- Ticker: 1707
- Exchange: TWSE
- Founded: 1969
- Industry: Personal Products
- Sector: Household
- Market Cap: NT$24.072b
- Shares outstanding: 148.14m
- Website: https://www.grapeking.com.tw
Number of Employees
- Grape King Bio Ltd
- Jinling Road
- No. 402, Section 2
- Taoyuan City
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/17 15:37|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.